Oral acute graft versus host disease after donor lymphocyte infusions: Clinicopathological characterization in a monocenter cohort.

Acute graft-versus-host disease (GVHD) Donor lymphocyte infusion (DLI) Hematopoietic stem cell transplant (HSCT) Lichenoid reaction Oral lesion Superficial mucoceles Xerostomia

Journal

Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118

Informations de publication

Date de publication:
03 2021
Historique:
received: 20 10 2020
accepted: 27 10 2020
pubmed: 15 11 2020
medline: 18 11 2021
entrez: 14 11 2020
Statut: ppublish

Résumé

Donor lymphocyte infusions (DLI) are used after hematopoietic stem cell transplant (HSCT) in order to boost the graft-versus-tumor effect. The most significant toxicity is acute or chronic graft-versus-host disease (GVHD), whose clinical symptoms mirror those occurring after HSCT. By contrast, oral acute GVHD lesions have been exceptionally described post-DLI. We report on a monocenter cohort of 12 adult patients that developed oral acute GVHD after DLI. The majority was treated for acute myeloid leukemia. A total of 29 DLI treatments were applied and the median time between the last DLI and the oral mucosal lesions was 42 days. Most patients presented these oral lesions concomitant with skin lesions and none of them had exclusive oral involvement. Oral lichenoid changes were observed in 11 patients, including plaque-like lesions and/or reticulated white streaks consistent with Wickham's striae, affecting mainly the buccal mucosa and dorsal or lateral aspects of the tongue. Mucosal histopathological findings showed a patchy-to-florid lichenoid interface dermatitis for 3 biopsied patients. Eight patients also experienced salivary gland changes. The treatment of oral lesions included high- to very high-potency topical corticosteroids in the majority of patients. Oral GVHD lesions have seldom been described after DLI, and only exceptionally in an acute setting. Our results are not consistent with those reported in the literature evaluating GVHD after DLI. In fact, oral acute GVHD lesions post-DLI appeared very common and similar to the oral lichenoid reactions of chronic GVHD following HSCT. The main limitations of this work are its retrospective design and the relatively small sample size.

Identifiants

pubmed: 33187825
pii: S1368-8375(20)30518-2
doi: 10.1016/j.oraloncology.2020.105082
pii:
doi:

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

105082

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Nuno Gomes (N)

Dermatovenereology Department, Centro Hospitalar Universitário de São João EPE - Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.

Anne Huynh (A)

Hematology Department, Institut Universitaire du Cancer Toulouse Oncopole, Centre Hospitalier Universitaire (CHU) de Toulouse, France - 1 avenue Irène Joliot-Curie 31059, Toulouse Cedex 9, France.

Cécile Borel (C)

Hematology Department, Institut Universitaire du Cancer Toulouse Oncopole, Centre Hospitalier Universitaire (CHU) de Toulouse, France - 1 avenue Irène Joliot-Curie 31059, Toulouse Cedex 9, France.

Sarah Guenounou (S)

Hematology Department, Institut Universitaire du Cancer Toulouse Oncopole, Centre Hospitalier Universitaire (CHU) de Toulouse, France - 1 avenue Irène Joliot-Curie 31059, Toulouse Cedex 9, France.

Christian Recher (C)

Hematology Department, Institut Universitaire du Cancer Toulouse Oncopole, Centre Hospitalier Universitaire (CHU) de Toulouse, France - 1 avenue Irène Joliot-Curie 31059, Toulouse Cedex 9, France.

Beatrice Barres (B)

Pathology Department, Institut Claudius REGAUD and Institut Universitaire du Cancer Toulouse Oncopole, Centre Hospitalier Universitaire (CHU) de Toulouse, France - 1 avenue Irène Joliot-Curie 31059, Toulouse Cedex 9, France.

Emmanuelle Vigarios (E)

Oral Medicine Department, Institut Claudius REGAUD and Institut Universitaire du Cancer Toulouse Oncopole, France - 1 avenue Irène Joliot-Curie 31059, Toulouse Cedex 9, France.

Vincent Sibaud (V)

Oncodermatology Department, Institut Claudius REGAUD and Institut Universitaire du Cancer Toulouse Oncopole, France - 1 avenue Irène Joliot-Curie 31059, Toulouse Cedex 9, France. Electronic address: sibaud.vincent@iuct-oncopole.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH